Search Results - "Wasiewski, Warren"

NXY-059 for the Treatment of Acute Ischemic Stroke by Shuaib, Ashfaq, Lees, Kennedy R, Lyden, Patrick, Grotta, James, Davalos, Antonio, Davis, Stephen M, Diener, Hans-Christoph, Ashwood, Tim, Wasiewski, Warren W, Emeribe, Ugochi

“…Two phase 3 clinical trials (SAINT I and SAINT II) evaluated the free-radical–trapping agent NXY-059 for the treatment of acute ischemic stroke. The SAINT I…”
Get full text

NXY-059 for Acute Ischemic Stroke by Lees, Kennedy R, Zivin, Justin A, Ashwood, Tim, Davalos, Antonio, Davis, Stephen M, Diener, Hans-Christoph, Grotta, James, Lyden, Patrick, Shuaib, Ashfaq, Hårdemark, Hans-Göran, Wasiewski, Warren W

“…This randomized placebo-controlled trial evaluated a free-radical–trapping agent (NXY-059) in patients with acute ischemic stroke. At 90 days, treatment with…”
Get full text

Safety and tolerability of NXY-059 for acute intracerebral hemorrhage : The CHANT trial by LYDEN, Patrick D, SHUAIB, Ashfaq, RODICHOK, Larry, WASIEWSKI, Warren W, AHLBERG, Gabrielle, LEES, Kennedy R, DAVALOS, Antoni, DAVIS, Stephen M, DIENER, Hans-Christoph, GROTTA, James C, ASHWOOD, Tim J, HARDEMARK, Hans-Goren, SVENSSON, Hannah H

“…NXY-059 is a free radical-trapping neuroprotectant developed for use in acute ischemic stroke. To facilitate prompt administration of treatment, potentially…”
Get full text

Ancrod in Acute Ischemic Stroke: Results of 500 Subjects Beginning Treatment Within 6 Hours of Stroke Onset in the Ancrod Stroke Program by LEVY, David E, DEL ZOPPO, Gregory J, DEMAERSCHALK, Bart M, DEMCHUK, Andrew M, DIENER, Hans-Christoph, HOWARD, George, KASTE, Markku, PANCIOLI, Arthur M, SPATAREANU, Carmen, WASIEWSKI, Warren W

“…Previous studies of multiple-day dosing with the defibrinogenating agent, ancrod, in acute ischemic stroke yielded conflicting results but suggested that a…”
Get full text

Hyperfibrinogenemia and Functional Outcome From Acute Ischemic Stroke by DEL ZOPPO, Gregory J, LEVY, David E, WASIEWSKI, Warren W, PANCIOLI, Arthur M, DEMCHUK, Andrew M, TRAMMEL, James, DEMAERSCHALK, Bart M, KASTE, Markku, ALBERS, Gregory W, RINGELSTEIN, Eric B

“…Epidemiological studies have found strong correlations between elevated plasma fibrinogen levels and both ischemic stroke incidence and stroke mortality…”
Get full text

Efficacy of Zolmitriptan Nasal Spray in Adolescent Migraine by Lewis, Donald W, Winner, Paul, Hershey, Andrew D, Wasiewski, Warren W, on behalf of Adolescent Migraine Steering Committee

“…The goal was to evaluate the efficacy and tolerability of zolmitriptan nasal spray in the treatment of adolescent migraine. The "Double-Diamond" study used a…”
Get full text

To phase 3 or not to phase 3? by Wasiewski, Warren W

Get full text

Clinical trials, devices, unproven treatments, and clinical equipoise by Wasiewski, Warren W, Johnston, Karen C

Get full text

Ancrod for Acute Ischemic Stroke: A New Dosing Regimen Derived from Analysis of Prior Ancrod Stroke Studies by Levy, David E., MD, Trammel, James, MS, Wasiewski, Warren W., MD

“…Background Ancrod, a fibrinogen-reducing agent, has been evaluated as treatment beginning within 3 or 6 hours of onset of acute ischemic stroke with…”
Get full text

Challenges and opportunities in designing clinical trials for neuromyelitis optica by Weinshenker, Brian G., Barron, Gerard, Behne, Jacinta M., Bennett, Jeffery L., Chin, Peter S., Cree, Bruce A.C., de Seze, Jerome, Flor, Armando, Fujihara, Kazuo, Greenberg, Benjamin, Higashi, Sayumi, Holt, William, Khan, Omar, Knappertz, Volker, Levy, Michael, Melia, Angela T., Palace, Jacqueline, Smith, Terry J., Sormani, Maria Pia, Van Herle, Katja, VanMeter, Susan, Villoslada, Pablo, Walton, Marc K., Wasiewski, Warren, Wingerchuk, Dean M., Yeaman, Michael R.

Get full text

Understanding the functional burden of CLN3 through the eyes of patients and families by Jackson, Skyler, Sebille, Marie, Wasiewski, Warren W., Kiser, Mary Beth, Engel, Patti A.

Get full text

NXY-059 for the Treatment of Acute Stroke : Pooled Analysis of the SAINT I and II Trials by DIENER, Hans-Christoph, LEES, Kennedy R, HARDEMARK, Hans-Goran, RODICHOK, Larry, LYDEN, Patrick, GROTTA, Jim, DAVALOS, Antoni, DAVIS, Stephen M, SHUAIB, Ashfaq, ASHWOOD, Tim, WASIEWSKI, Warren, ALDERFER, Vivian

“…In animal models of acute ischemic stroke (AIS), the free radical-trapping agent NXY-059 showed promise as a neuroprotectant. SAINT I and II were randomized,…”
Get full text

The Placebo Responder Rate in Children and Adolescents by Lewis, Donald W., Winner, Paul, Wasiewski, Warren

Get full text

Challenges and opportunities in designing clinical trials for neuromyelitis optica by Weinshenker, Brian G, Barron, Gerard, Behne, Jacinta M, Bennett, Jeffery L, Chin, Peter S, Cree, Bruce A.C, de Seze, Jerome, Flor, Armando, Fujihara, Kazuo, Greenberg, Benjamin, Higashi, Sayumi, Holt, William, Khan, Omar, Knappertz, Volker, Levy, Michael, Melia, Angela T, Palace, Jacqueline, Smith, Terry J, Sormani, Maria Pia, Van Herle, Katja, VanMeter, Susan, Villoslada, Pablo, Walton, Marc K, Wasiewski, Warren, Wingerchuk, Dean M, Yeaman, Michael R

“…Current management of neuromyelitis optica (NMO) is noncurative and only partially effective. Immunosuppressive or immunomodulatory agents are the mainstays of…”
Get full text

Home Time Is Extended in Patients With Ischemic Stroke Who Receive Thrombolytic Therapy: A Validation Study of Home Time as an Outcome Measure by MISHRA, Nishant K, SHUAIB, Ashfaq, LYDEN, Patrick, DIENER, Hans-Christoph, GROTTA, James, DAVIS, Stephen, DAVALOS, Antoni, ASHWOOD, Tim, WASIEWSKI, Warren, LEES, Kennedy R

“…"Home time" (HT) refers to the number of days over the first 90 after stroke onset that a patient spends residing in their own home or a relative's home versus…”
Get full text

Neuromyelitis optica relapses: Race and rate, immunosuppression and Impairment by Tackley, George, O’Brien, Fanny, Rocha, João, Woodhall, Mark, Waters, Patrick, Chandratre, Saleel, Halfpenny, Christopher, Hemingway, Cheryl, Wassmer, Evangeline, Wasiewski, Warren, Leite, Maria Isabel, Palace, Jacqueline

“…Abstract Objective Neuromyelitis optica (NMO) is a rare antibody-mediated CNS disease characterised by disabling relapses leading to high morbidity and…”
Get full text

Zolmitriptan Oral Tablet in Migraine Treatment: High Placebo Responses in Adolescents by Rothner, A. David, Wasiewski, Warren, Winner, Paul, Lewis, Donald, Stankowski, Jill

“…Objective.—The objective of this randomized, double‐blind, placebo‐controlled study was to evaluate the efficacy and tolerability of the zolmitriptan…”
Get full text

Additional outcomes and subgroup analyses of NXY-059 for acute ischemic Stroke in the SAINT I trial by LEES, Kennedy R, DAVALOS, Antonio, EMERIBE, Ugochi, ZIVIN, Justin A, DAVIS, Stephen M, DIENER, Hans-Christoph, GROTTA, James, LYDEN, Patrick, SHUAIB, Ashfaq, ASHWOOD, Tim, HARDEMARK, Hans-Goran, WASIEWSKI, Warren

“…NXY-059 is a free radical-trapping neuroprotectant demonstrated to reduce disability from ischemic stroke. We conducted analyses on additional end points and…”
Get full text

Efficacy of zolmitriptan nasal spray in adolescent migraine by LEWIS, Donald W, WINNER, Paul, HERSHEY, Andrew D, WASIEWSKI, Warren W

Get full text

Equilibrium binding of thrombin to platelets by Martin, Bernice M, Wasiewski, Warren W, Fenton, John W, Detwiler, Thomas C

“…Binding of human [125I]thrombin to washed human platelets was studied in order to analyze the nonenzymic aspects of the thrombin stimulation of platelets…”
Get full text